Updated
Updated · MarketWatch · Apr 28Sun Pharmaceutical Industries shares rise 0.80 percent, outperforming competitors
12 articles · Updated · MarketWatch · Apr 28
- The company's stock closed at 1,747.70 rupees on Tuesday, even as the BSE SENSEX Index fell 0.54%.
- Trading volume reached 214,221, well above the 50-day average of 138,968, while Sun Pharma remained 5.58% below its 52-week high.
- Competitors Zydus Lifesciences and Shilpa Medicare declined, while Dr. Reddy's Laboratories gained 1.51% during the same session.
Analysts are divided: could Sun Pharma's biggest-ever acquisition actually cause its long-term valuation to fall? Sun Pharma is now a biosimilar giant. How will its rivals respond to this sudden market disruption? After its record-breaking deal, can Sun Pharma manage massive debt while still innovating for the future? What does India's largest foreign pharma deal signal about the future of the global pharmaceutical industry? Will one of the world's biggest pharma mergers make crucial women's health drugs more or less affordable?